MOTS-c dosing & administration
A remarkable 16-amino-acid peptide encoded by your mitochondrial DNA that acts as an 'exercise mimetic'—boosting metabolism, improving insulin sensitivity, and helping your cells adapt to metabolic stress just like a good workout would [1][3].
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
2 documented dose levels — separate regimens, not a titration schedule
5 mg
Frequency
2-3 times per week
Duration
4-week cycle
10 mg
Frequency
2-3 times per week
Duration
4-8 week cycle, then washout
Upper end of the commonly used research/practice range, cycled with a washout period.
Timing
Best time to take
Morning injections work best for most people since MOTS-c affects metabolic pathways that are naturally more active earlier in the day. Taking it before or after morning exercise may enhance its effects.
With food?
MOTS-c can be taken regardless of food timing for injections. However, some users prefer taking it fasted.
If stacking
If stacking with other peptides, inject them at different sites. MOTS-c pairs well with longevity-focused compounds like Epithalon or NAD+ precursors. If using alongside blood sugar-lowering supplements like berberine, monitor glucose levels carefully.
Adjusting your dose
Increase if
- You've completed the starting protocol with zero issues for at least 1-2 weeks
- You're not noticing metabolic improvements at current dose
- Your research goals require exploring higher dose ranges
Decrease if
- You experience persistent fatigue that doesn't improve after the first week
- Blood glucose drops lower than comfortable (if monitoring)
- Injection site reactions don't resolve within 48 hours
- Any unexpected or uncomfortable side effects arise
Signs of right dose
- Improved energy levels, especially during physical activity
- Better blood glucose readings if you're monitoring
- Stable or improved body composition with consistent diet
- No injection site issues beyond initial mild redness
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (just under the skin)—the easiest and most common method for self-administration
Best sites
Storage
Before reconstitution
Keep your MOTS-c powder in the refrigerator (36-46°F / 2-8°C) for short-term storage or in the freezer (-4°F / -20°C) for long-term storage. Store in the original sealed vial away from light. Properly stored powder can remain stable for 2+ years when frozen.
After reconstitution
Once mixed with bacteriostatic water, refrigerate at 36-46°F (2-8°C). Never freeze the reconstituted solution—freezing destroys the peptide. Keep away from light and use within 21-28 days.
Signs of degradation — discard the vial
Sample daily schedule
Morning (6-9 AM, ideally before or after light exercise)
5-15 mg depending on protocol injection
Site: Rotate between belly, thigh, and arm
Morning timing aligns with your body's natural metabolic cycles when AMPK activity and insulin sensitivity are optimized. Follow a 4-6 week cycle, then take 2-4 weeks off before repeating.
Safety
Is it safe?
Side effects
Commonly reported: Injection site redness, Mild fatigue, Mild headache
Less common: Changes in appetite, Mild hypoglycemia symptoms
Stop and seek help if
- Any signs of allergic reaction—stop immediately and seek medical help
- Persistent fatigue that doesn't improve after the first week
- Recurrent hypoglycemia symptoms, especially if you're diabetic
- Injection site reactions that spread or don't heal
- Any side effect that feels serious or really concerns you
- Your research protocol/cycle is complete
MOTS-c is a research compound, not an FDA-approved medication. Never start, stop, or change your dosing without guidance from a qualified healthcare provider. This information is for educational purposes only—not medical advice.
Flagged pairings
- Insulin — MOTS-c improves insulin sensitivity, which could significantly increase hypoglycemia risk. Reduce insulin dose and monitor closely with your doctor.
- Sulfonylureas (glyburide, glipizide) — Both lower blood sugar—increased hypoglycemia risk. Consult your doctor before combining.
Published research
What the studies show
Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P · 2015
This groundbreaking discovery paper identified MOTS-c as a new hormone encoded in mitochondrial DNA. The researchers showed that MOTS-c targets skeletal muscle, activates AMPK, and prevents both age-dependent and diet-induced insulin resistance and obesity in mice—establishing it as a genuine metabolic regulator.
Lee C, Kim KH, Cohen P · 2016
This review confirmed MOTS-c's role as a 'mitochondrial hormone' with far-reaching effects. It explained how MOTS-c inhibits the folate cycle and purine biosynthesis, leading to AMPK activation—making it a potential therapeutic target for obesity, diabetes, and aging-related metabolic decline.
Feng Y, Rao Z, Tian X, Hu Y, Yue L, Meng Y, Zhong Q, Chen W, Xu W, Li H, Hu Y, Shi R · 2024
This study in marathon runners and mice revealed that MOTS-c levels closely correlate with aerobic exercise capacity. Endurance training boosts MOTS-c secretion, which enhances mitochondrial function through AMPK/PGC-1α activation—suggesting MOTS-c mediates some of exercise's metabolic benefits.
Kumagai H, Kim SJ, Miller B, et al. · 2024
Researchers discovered that MOTS-c directly binds and activates the CK2 enzyme, which is required for its muscle-protective effects. The study also found that a natural MOTS-c variant (K14Q) with reduced CK2 binding is associated with higher sarcopenia and type 2 diabetes risk—providing the first genetic link between MOTS-c and human metabolic disease.
Gudiksen A, Hansen CC, van der Stede T, et al. · 2026
This study demonstrated that MOTS-c administration improves mitochondrial bioenergetic performance in skeletal muscle through PGC-1α and AMPK pathways. Importantly, it reduced mitochondrial reactive oxygen species and oxidative damage, showing MOTS-c protects cells from the harmful byproducts of energy production.
Kim KH, Son JM, Benayoun BA, Lee C · 2018
In cultured cells, MOTS-c moved from the mitochondria into the nucleus within about 30 minutes of metabolic stress such as glucose restriction, serum removal, or oxidative stress, and this movement depended on AMPK. Once in the nucleus, MOTS-c bound antioxidant response element (ARE) sequences in genes including HO-1 and NQO1 and interacted with the stress-response transcription factor NRF2, increasing expression of those genes.
D'Souza RF, Woodhead JST, Hedges CP, Zeng N, Wan J, Kumagai H, Lee C, Cohen P, Cameron-Smith D, Mitchell CJ, Merry TL · 2020
In healthy men, circulating MOTS-c was 11% lower in middle-aged men (45-55 y) and 21% lower in older men (70-81 y) than in young men (18-30 y), and the age effect remained statistically significant after adjusting for body composition and metabolic measures. Skeletal muscle MOTS-c moved in the opposite direction, being roughly 1.5-fold higher in the older groups, and plasma MOTS-c was not correlated with HOMA-IR.
Yang L, Li M, Liu Y, Bai Y, Yin T, Chen Y, Jiang J, Liu S · 2024
Alongside its main findings on pain behaviour, this mouse study assessed organ safety after long-term intraperitoneal MOTS-c dosing. Chronic administration had little effect on liver, renal, lipid, or cardiac function measures, and no differences in histological damage to liver, spleen, or kidney were seen between treated and control groups.
LaMoia TE, Shulman GI · 2021
This review states that metformin's glucose-lowering effect in people with poorly controlled type 2 diabetes comes primarily from inhibiting hepatic glucose production, and reviews the clinical studies in patients that confirmed this. It also traces metformin's clinical history from its 1957 introduction by Jean Sterne through FDA approval in 1994.
U.S. Food and Drug Administration, CDER (Li J, Poon N-L, Asante K, Albuquerque E, Benedict A, San Antonio M, Kasim S) · 2026
FDA review (dated 5/11/2026) of MOTS-c (free base) and MOTS-c acetate for the 503A bulks list. States there is no USP/NF monograph and neither is a component of an FDA-approved drug; FDA did not identify clinical studies evaluating the proposed uses, found no published studies in which MOTS-c products were used in humans, and did not identify any clinical studies or human exposure data for MOTS-c via any route, so potential safety risks in humans are unknown. FAERS searches through March 9, 2025 retrieved no adverse-event reports. Nonclinical pharmacology is limited to in-vitro and rodent models without dose-response assessment, and FDA did not identify nonclinical toxicity studies. Raises immunogenicity concern for subcutaneous peptide injection. The nominated products were 5 mg and 10 mg for subcutaneous injection. Notes MOTS-c is listed as prohibited in Global DRO from the 2024 WADA Prohibited List. FDA proposed not adding MOTS-c or MOTS-c acetate to the 503A Bulks List.
Head to head
MOTS-c compared
Studied for
Conditions MOTS-c has been researched in
Want the full picture?
The complete MOTS-c research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.